Amarin Corp. said it will fire about half of its employees after a U.S. Food and Drug Administration advisory panel failed to back expanded use of its fish-oil pill Vascepa for those with high levels of fat in their blood.
Amarin Corp. lost more than half its value after the company failed to win the backing of U.S. advisers to expand use of its fish-oil pill Vascepa for those with high levels of fat in their blood.
Amarin’s fish-oil pill Vascepa failed to win the backing of U.S. advisers to significantly expand its use for those with high levels of fat in their blood.
Expanding the use of Amarin Corp.’s fish oil drug Vascepa, approved last year to treat “very high” triglycerides, may depend on the outcome of a study on heart risks, U.S. regulators said.
Teva Pharmaceuticals USA Inc. and Par Pharmaceutical Cos. won an appeal in their bid to sell a generic version of BASF SE’s heart medicine Lovaza in the U.S.
Fish oil has been touted as useful for everything from growing hair to treating clinical depression. Now drug makers are stepping up their promotion of its benefits for treating heart disease.
Taking fish oil before and after cardiac surgery didn’t prevent a form of irregular heartbeat in a study finding that raises more questions about the extent of the supplement’s health benefits.
The consumption of polyunsaturated fatty acids found primarily in fish is linked to a 14 percent decline in breast-cancer risk, according to a new study.
Looks like a fish oil pill a day won’t keep the doctor away.